Esperion Therapeutics (ESPR) to Release Quarterly Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.03. The business had revenue of $32.25 million for the quarter, compared to analysts’ expectations of $26.84 million. During the same quarter in the prior year, the firm earned ($0.76) earnings per share. On average, analysts expect Esperion Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Price Performance

ESPR traded down $0.02 during trading on Tuesday, hitting $1.98. The company had a trading volume of 1,124,687 shares, compared to its average volume of 6,593,926. The business has a 50-day moving average of $2.39 and a 200-day moving average of $2.02. Esperion Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.40. The company has a market cap of $374.07 million, a PE ratio of -0.94 and a beta of 0.84.

Analyst Upgrades and Downgrades

ESPR has been the topic of a number of recent analyst reports. Bank of America lowered Esperion Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Esperion Therapeutics in a research note on Wednesday, April 10th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research note on Monday, March 25th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.33.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.